Bern-based health data analysis startup RetinAI has landed CHF 2.3 million in a funding round led by btov Partners, with participation of Swiss-based investor network investiere and a consortium of private investors. The startup plans to use the money to hire more people and accelerate certification of its solutions.
Founded in 2016, RatinAI has developed a product called “Discovery Platform,” which applies AI to clinical and research workflows at eye clinics and health institutions. Its algorithms help with detection of several conditions like age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, as well as for monitoring disorders like Alzheimer, multiple sclerosis, Parkinson, and more.
"One of the biggest issues you find in health institutions is the lack of structure in data originating from medical devices or electronic health records,” said RetinAI CEO Carlos Ciller. “This situation makes it complicated to identify patterns related to an eye condition in a reasonable amount of time. At RetinAI we bring data organisation and analysis to the next level, digesting and funnelling information using our algorithms and presenting it to the user in a rich manner. As a result, clinicians can reach conclusions and take actions faster than ever before.”